Three notable events occurred during the weekend and none of them are really all that notable, more like expected. Friday in a move that should surprise no one the FDA rejected sotagliflozin confirming once more when it comes to diabetes Sanofi has the reverse Midas touch. Even if the FDA had approved the drug it really didn’t have much of a future and would have done little to offset what Sanofi is losing in the insulin space.
Next at ENDO 2019: The Endocrine Society Annual Meeting in New Orleans what looked like big news was a study revealed that . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.